Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

NCT05756322 is registered in ClinicalTrials.gov with Lin BioScience, Inc as lead sponsor.

NCT NCT05756322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05756322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Lead sponsor
Lin BioScience, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 20, 2023
Completion date
December 31, 2026
Enrollment
90 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or resistant acute leukaemias